Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy

Tomoko Fujiyuki; Yosuke Amagai; Koichiro Shoji; Takeshi Kuraishi; Akihiro Sugai; Mutsumi Awano; Hiroki Sato; Shosaku Hattori; Misako Yoneda; Chieko Kai

doi:10.1016/j.omto.2020.09.007

Publisher Website

Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy

Authors

Fujiyuki, Tomoko¹
Amagai, Yosuke¹
Shoji, Koichiro¹
Kuraishi, Takeshi²
Sugai, Akihiro¹
Awano, Mutsumi¹
Sato, Hiroki¹
Hattori, Shosaku²
Yoneda, Misako¹
Kai, Chieko¹

¹ Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
² Amami Laboratory of Injurious Animals, The Institute of Medical Science, The University of Tokyo, 802 Tean-Sude, Setouchisho, Oshima-gun, Kagoshima 894-1531, Japan

Type

Published Article

Journal

Molecular Therapy Oncolytics

Publisher

American Society of Gene & Cell Therapy

Publication Date

Sep 30, 2020

Volume

19

Pages

127–135

Identifiers

DOI: 10.1016/j.omto.2020.09.007

PMID: 33145396

PMCID: PMC7585052

Source

PubMed Central

Keywords

License

Unknown

Abstract

Triple negative breast cancer (TNBC) is one of the most refractory breast cancer types. A recombinant measles virus, rMV-SLAMblind, infected nectin-4-positive TNBC cells and significantly suppressed the tumor growth in xenograft models. Thus, rMV-SLAMblind is a promising candidate as a therapeutic agent for TNBC.

Report this publication

Statistics

Seen <100 times